Quarterly ResultMay 13, 2026, 07:38 AM
Arbutus Biopharma Q1 Net Income $169.7M on Moderna Settlement
AI Summary
Arbutus Biopharma reported a significant financial turnaround in Q1 2026, driven by an anticipated $178.7M payment from a settlement agreement with Moderna. The company posted a net income of $169.7M, a substantial improvement from a loss of $24.5M in the prior year's quarter, with total revenue reaching $179.1M. Arbutus also maintained $95.2M in cash, cash equivalents, and marketable securities, and continues its patent litigation against Pfizer/BioNTech while holding global rights for imdusiran.
Key Highlights
- Arbutus expects to receive $178.7M from the Moderna settlement by July 8, 2026.
- Q1 2026 net income was $169.7M, a significant increase from a $(24.5)M loss in Q1 2025.
- Total revenue surged to $179.1M in Q1 2026, up from $1.8M in Q1 2025.
- Basic EPS was $0.88 in Q1 2026, compared to $(0.13) in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $95.2M as of March 31, 2026.
- Research and development expenses decreased to $4.1M in Q1 2026 from $9.0M in Q1 2025.
- The company continues its patent infringement lawsuit against Pfizer and BioNTech.
- Global rights for imdusiran were regained after the Qilu partnership termination in June 2025.
Price Impact
More from ABUS